Portfolio PR – Page 2 – Sound Bioventures

All Events Fund articles Fund PR Portfolio articles Portfolio PR

NephroDI Therapeutics Announces Investment by Sound Bioventures to Accelerate Development of NDI-5001 as a Potential First-in-Class Therapy for Pediatric Orphan Kidney Disease

2024.06.202024.09.04 / New funding to take NDI-5001 into and through clinical proof of concept in Congenital Nephrogenic Diabetes Insipidus (NDI) New investment complements previously announced strategic corporate part ...

ARTHEx biotech

ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)

2024.02.282024.05.13 / -ATX-01 is the industry’s first microRNA therapeutic to be evaluated for DM1 and the first program from ARTHEX’s pipeline to enter the clinic – -First patient expected to be enrolled in Q2 2024- ...

Artax Announces First Patient Dosed in Phase 2a Psoriasis Trial Evaluating AX-158.

2024.02.132024.05.13 / Safety and Efficacy Results Are Expected in Second Half of 2024 Evaluating AX-158, a First in Class Nck Blocker, Shifting the Paradigm of Autoimmune Disease Treatment. AX-158 Has Broad Poten ...

Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy

2024.01.252024.05.13 / • Investigating potential for an oral treatment in diabetic retinopathy• First patient dosed in Phase 1b/2a clinical trial Copenhagen, Denmark, 25 January 2024 – Breye Therapeutics ApS (Breye), a ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Granted Clinical Trial Authorization for AX-158 Phase 2a Psoriasis Study

2024.01.092024.05.13 / Patient Enrollment Expected to Begin by Year End Phase 2a Study Seeks to Demonstrate the Safety and Efficacy of AX-158 in Patients with Mild-to-Moderate Psoriasis, Further Advancing a New Approach ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Announces Executive Team Changes, Expansion as Company Heads into Pivotal 2024 Year

2024.01.042024.05.13 / Former Board Chair Dr. Rob Armstrong Now Artax CEO as Joseph Lobacki Moves to Advisory Role Additional Promotions Include Dr. Andre Hoekema to Board Chair, Dr. Maria Nichol to Chief Business Offic ...

AbolerIS Pharma Announces €27 Million in Series A Financing to Advance its Novel Treatment Paradigm for Autoimmune and Inflammatory Diseases

2023.09.192024.05.13 / Financing round led by Caixa Capital Risc and co-led by Sound Bioventures and existing investor Newton Biocapital. AbolerIS is developing a first-in-class drug inducing an immune tolerance-b ...

Golgi Neurosciences and Breye Therapeutics announce successful closing of P2X7 receptor antagonist program transfer

2023.08.082025.06.25 / 25 July 2023 Collaboration to advance development of innovative oral small molecule therapeutics for retinal disorders Milan, Italy and Copenhagen, Denmark, 25 July 2023 – Golgi Neuroscien ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Biopharma Announces Positive Phase 1 Results for AX-158, Company’s First-in-Class Oral Immunomodulator Developed to Treat T Cell-Mediated Diseases

2023.06.022024.05.13 / Phase 1 Findings Demonstrated that Investigational Agent AX-158 Was Well Tolerated at All Doses, with a Profile that Strongly Supports Further Clinical Development Efforts AX-158 is Being Develope ...

VarmX raises €30 million Series B2 financing for IND approvaland preparations for pivotal trial

2023.05.252024.05.13 / Sound Bioventures and EIC Fund join existing investors EQT Life Sciences (formerly LSP),Inkef, Lundbeckfonden BioCapital, Ysios Capital, BioGeneration Ventures, InnovationQuarter and Libertatis Ergo ...

ARTHEx biotech

We are excited to welcome Arthex to our portfolio

2023.05.032024.09.09 / ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1) The ArthemiRTM trial, a Phase I-IIa study of ATX-01 in DM ...

Breye Therapeutics Strengthens Management Team and Board

2023.04.202025.06.25 / Industry veteran Dr. Peter Adamson, PhD appointed as Chief Scientific Officer Dr. Gabriela Burian, MD appointed to the Board of Directors Copenhagen, Denmark, 20 April 2023 – Breye Therapeuti ...